Silence Therapeutics plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Silence Therapeutics plc (SLNCF) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 110.38 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-03-05
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 110.38K shares, a 75.90% decline from fiscal 2024.
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 458.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|
| 2025-12-31 | 110.38K shares 10-K · filed 2026-03-05 |
| 2024-12-31 | 458.00K shares 10-K · filed 2025-02-27 |